# US 2024/0201202 A1 · METHODS FOR DETECTING IMMUNOGLOBULIN G, SUBCLASS 4 (IgG4) IN A BIOLOGICAL SAMPLE

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0201202 A1
- Document ID: US20240201202A1
- Status: Published application
- Kind: A1
- Application number: 18/586,721
- Filed: 2024-02-26
- Published: 2024-06-20
- Earliest claimed: 2021-08-27
- Assignees: Abbott Laboratories
- Applicants: Abbott Laboratories
- Inventors: Nicolette Jeanblanc; Susan Brophy; Bryan TIEMAN; Himali SONI; Salman ALI
- Web page: https://patentgrep.com/patent/US20240201202A1

## CPC

- G01N 33/6854: {Immunoglobulins}
- G01N 21/59: Transmissivity (G01N21/25 takes precedence)
- G01N 33/54313: {the carrier being characterised by its particulate form}
- G01N 2800/26: Infectious diseases, e.g. generalised sepsis
- G01N 2800/7095: Inflammation
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed herein are methods, kits, and systems for detecting or determining an amount, quantity, concentration and/or level of immunoglobulin G, subclass 4 (LgG4) in a biological sample from a subject. Particularly, the methods, kits and systems are directed to detection of IgG4 using an anti-IgG4 antibody that does not cross-react with other IgG subclasses.

## Claims

### Claim 1

A method of detecting immunoglobulin G, subclass 4 (IgG4) in a biological sample, wherein the method comprises performing an assay on the biological sample obtained from a subject, wherein the assay includes adding an anti-IgG4 antibody capture reagent to the biological sample, wherein the anti-IgG4 antibody capture reagent comprises an anti-IgG4 antibody immobilized on a solid support, wherein the anti-IgG4 antibody does not cross-react with other IgG subclasses.

### Claim 2 (depends on 1)

The method of claim 1, wherein the assay further comprises incubating the anti-IgG4 antibody capture reagent with the biological sample for a period of time.

### Claim 3 (depends on 1)

The method of claim 1, wherein the assay further comprises measuring turbidity.

### Claim 4 (depends on 3)

The method of claim 3, wherein the assay further comprises comparing at least one turbidity measurement to a standard and quantifying an amount of the IgG4 in the biological sample.

### Claim 5 (depends on 4)

The method of claim 4, wherein turbidity is measured by loss of intensity or increase in absorbance of transmitted light through the biological sample at a wavelength of about 570 nm.

### Claim 6 (depends on 1)

The method of claim 1, wherein the anti-IgG4 antibody is a monospecific antibody.

### Claim 7 (depends on 6)

The method of claim 6, wherein the monospecific antibody is directed to a linear epitope.

### Claim 8 (depends on 6)

The method of claim 6, wherein the monospecific antibody is directed to a conformational epitope.

### Claim 9 (depends on 1)

The method of claim 1, wherein the anti-IgG4 antibody is a monoclonal antibody.

### Claim 10 (depends on 1)

The method of claim 1, wherein the anti-IgG4 antibody is selected from the group consisting of: 3H293, 0.B.27, 5C7, IGHG4/1345 and IGHG4/2042A.

### Claim 11 (depends on 1)

The method of claim 1, wherein the solid support is a microparticle.

### Claim 12 (depends on 1)

The method of claim 1, wherein the microparticle comprises latex.

### Claim 13 (depends on 1)

The method of claim 1, wherein the assay is performed in about 1 minute, in about 5 minutes, in about 10 minutes, in about 15 minutes or in about 20 minutes.

### Claim 14 (depends on 1)

The method of claim 1, wherein the biological sample is whole blood, serum, or plasma.

### Claim 15 (depends on 1)

The method of claim 1, wherein the assay is an immunoassay or a clinical chemistry assay.

### Claim 16 (depends on 1)

The method of claim 1, wherein the method is performed using single molecule detection, lateral flow, or a point-of care method.

### Claim 17

In an improvement of a method of detecting immunoglobulin G, subclass 4 (IgG4) in a biological sample, wherein the method comprises performing an assay on the biological sample obtained from a subject, wherein the assay includes adding an anti-IgG4 antibody capture reagent to the biological sample, wherein the anti-IgG4 antibody capture reagent comprises an anti-IgG4 antibody immobilized on a solid support, wherein the improvement comprises using an anti-IgG4 antibody that does not cross-react with other IgG subclasses.

### Claim 18 (depends on 17)

The improvement of claim 17, wherein the assay further comprises incubating the anti-IgG4 antibody capture reagent with the biological sample for a period of time.

### Claim 19 (depends on 17)

The improvement of claim 17, wherein the assay further comprises measuring turbidity.

### Claim 20 (depends on 19)

The improvement of claim 19, wherein the assay further comprises comparing at least one turbidity measurement to a standard and quantifying an amount of the IgG4 in the biological sample.

### Claim 21 (depends on 20)

The improvement of claim 20, wherein turbidity is measured by loss of intensity or increase in absorbance of transmitted light through the biological sample at a wavelength of about 570 nm.

### Claim 22 (depends on 17)

The improvement of claim 17, wherein the anti-IgG4 antibody is a monospecific antibody.

### Claim 23 (depends on 22)

The improvement of claim 22, wherein the monospecific antibody is directed to a linear epitope.

### Claim 24 (depends on 22)

The improvement of claim 22, wherein the monospecific antibody is directed to a conformational epitope.

### Claim 25 (depends on 17)

The improvement of claim 17, wherein the anti-IgG4 antibody is a monoclonal antibody.

### Claim 26 (depends on 17)

The improvement of claim 17, wherein the anti-IgG4 antibody is selected from the group consisting of: 3H293, 0.B.27, 5C7, IGHG4/1345 and IGHG4/2042A.

### Claim 27 (depends on 17)

The improvement of claim 17, wherein the solid support is a microparticle.

### Claim 28 (depends on 17)

The improvement of claim 17, wherein the microparticle comprises latex.

### Claim 29 (depends on 17)

The improvement of claim 17, wherein the assay is performed in about 1 minute, in about 5 minutes, in about 10 minutes, in about 15 minutes or in about 20 minutes.

### Claim 30 (depends on 17)

The improvement of claim 17, wherein the biological sample is whole blood, serum, or plasma.

### Claim 31 (depends on 17)

The improvement of claim 17, wherein the assay is an immunoassay or a clinical chemistry assay.

### Claim 32 (depends on 17)

The improvement of claim 17, wherein the method is performed using single molecule detection, lateral flow, or a point-of care method.

### Claim 33

Use of an anti-IgG4 antibody capture reagent for detecting immunoglobulin G, subclass 4 (IgG4) in a biological sample, wherein the anti-IgG4 antibody capture reagent comprises an anti-IgG4 antibody immobilized on a solid support, wherein the anti-IgG4 antibody does not cross-react with other IgG subclasses.

### Claim 34 (depends on 33)

Use of claim 33, wherein the anti-IgG4 antibody is a monospecific antibody.

### Claim 35 (depends on 34)

Use of claim 34, wherein the monospecific antibody is directed to a linear epitope.

### Claim 36 (depends on 34)

Use of claim 34, wherein the monospecific antibody is directed to a conformational epitope.

### Claim 37 (depends on 33)

Use of claim 33, wherein the anti-IgG4 antibody is a monoclonal antibody.

### Claim 38 (depends on 33)

The use of claim 33, wherein the anti-IgG4 antibody is selected from the group consisting of: 3H293, 0.B.27, 5C7, IGHG4/1345 and IGHG4/2042A.

### Claim 39 (depends on 33)

The use of claim 33, wherein the solid support is a microparticle.

### Claim 40 (depends on 33)

The use of claim 33, wherein the microparticle comprises latex.

### Claim 41 (depends on 33)

The use of claim 33, wherein the assay is performed in about 1 minute, in about 5 minutes, in about 10 minutes, in about 15 minutes or in about 20 minutes.

### Claim 42 (depends on 33)

The use of claim 33, wherein the biological sample is whole blood, serum, or plasma.
